Skip to main content

Table 3 Changes of medication from baseline to 12 and 24 months follow-up among groups, between group differences, and interaction between group and time

From: Patient-centered communication and shared decision making to reduce HbA1c levels of patients with poorly controlled type 2 diabetes mellitus - results of the cluster-randomized controlled DEBATE trial

  Intervention group Control group Between group differences
Change from baseline Change from baseline Intervention group - Control group
Outcome variables N Mean SD Adjusted Mean 95% CI p Value N Mean SD Adjusted Mean 95% CI p Value Adjusted Mean 95% CI p Value
Sum of all diabetes medication
 Baseline 435 1.98 0.8      398 2.02 0.8         
 12 months follow up 378 2.09 0.9 0.05 −0.03 0.12 0.2170 342 2.11 0.9 0.09 0.01 0.17 0.0274 −0.04 −0.14 0.06 0.4316
 24 months follow up 339 2.14 0.9 0.14 0.06 0.22 0.0006 305 2.25 0.9 0.18 0.10 0.27 <.0001
Insulin
 Baseline 435 0.97 0.9      398 0.97 0.9         
 12 months follow up 378 1.08 0.9 0.09 0.03 0.15 0.0021 342 1.13 0.8 0.14 0.08 0.20 <.0001 −0.05 −0.12 0.03 0.2293
 24 months follow up 339 1.17 0.9 0.20 0.14 0.26 <.0001 305 1.22 0.9 0.25 0.18 0.31 <.0001
Sulfonylurea
 Baseline 435 0.19 0.4      398 0.21 0.4         
 12 months follow up 378 0.20 0.4 −0.00 −0.04 0.03 0.8920 342 0.17 0.4 −0.02 −0.05 0.01 0.2591 0.02 −0.03 0.06 0.4506
 24 months follow up 339 0.16 0.4 −0.04 − 0.08 −0.01 0.0195 305 0.15 0.4 −0.06 −0.10 − 0.02 0.0014
Other diabetes medication
 Baseline 435 0.01 0.1      398 0.01 0.1         
 12 months follow up 378 0.02 0.1 0.01 −0.01 0.03 0.4477 342 0.03 0.2 0.01 −0.01 0.03 0.1829 −0.01 −0.03 0.02 0.6704
 24 months follow up 339 0.05 0.2 0.04 0.02 0.07 0.0003 305 0.07 0.2 0.05 0.03 0.07 <.0001